BPB Reports
Online ISSN : 2434-432X
Regular Article
Analysis of Metformin-Associated Lactic Acidosis using the Japanese Adverse Drug Event Report Database
Nanaka IchiharaMika MaezawaSatoshi NakaoKoumi MiyasakaSakiko HirofujiMoe YamashitaYuka NokuraKensuke MatsuiHiroaki UranishiMayumi KitamuraMegumi HoribeKazuhiro IguchiMitsuhiro Nakamura
Author information
JOURNAL OPEN ACCESS FULL-TEXT HTML
Supplementary material

2024 Volume 7 Issue 3 Pages 76-80

Details
Abstract

Aim: In 2010, the maximum dosage of metformin was increased in Japan to the maximum dosage approved in the United States. This study aimed to evaluate the impact of the revised dosage in the package insert on metformin-associated lactic acidosis (MALA) reports in Japanese patients using the Japanese Adverse Drug Event Report (JADER) database. Methods: Adjusted reporting odds ratios of MALA was evaluated using multiple logistic regression models. Trends were analyzed using the Mann–Kendall test and Pettitt's test. Receiver operating characteristic (ROC) curve analysis was used to estimate the metformin dose that influenced MALA development. Results: The JADER database contains 845,956 reports submitted between April 2004 and March 2023. The number of adverse event reports and mean dose increased after the 2010 revision of the package insert. According to the ROC curve for lactic acidosis, the cutoff value was 1000.0 mg/day. Conclusions: Increase in metformin doses owing to regulatory actions and the recommendation of the Japan Diabetes Society may have influenced the increased MALA reporting rate, suggesting a dose-dependent relationship between the drug and MALA. The cutoff for the daily dose of metformin associated with MALA was the current maintenance dose listed in the package insert. We believe that MALA development must be carefully monitored in Japan even at the dosage specified in the package insert.

Content from these authors
© 2024 The Pharmaceutical Society of Japan

BPB Reports applies the Creative Commons Attribution (CCBY) license to works we published. The license was developed to facilitate open access - namely, free immediate access to, and unrestricted reuse of, original works to all types. Under this license, authors agree to make articles legally available for reuse, without permissions of fees, for virtually any purpose. Anyone may copy, distribute, or reuse these articles, as long as the author and original source are properly cited.
https://creativecommons.org/licenses/by/4.0/
Previous article Next article
feedback
Top